Groupe d'Etude en Oncologie du Quebec

Titre	Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
Protocole ID	LIVEN (P23-363)
ClinicalTrials.gov ID	NCT05424562
Type(s) de cancer	Leucémie myéloïde aiguë (LMA)
Phase	Autres
Type étude	Autre
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	Montréal
Investigateur(trice) principal(e)	Dr John Storring
Coordonnateur(trice)	Judit Kokai 438-888-1582
Statut	Actif en recrutement
Date d'activation	27-01-2023
Critètes d'éligibilité	Diagnosis of Acute Myeloid Leukemia (AML). Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice. Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.
Critètes d'exclusion	Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Groupe d'étude en oncologie du Québec